Wobrock, Thomas

[["dc.bibliographiccitation.firstpage","142"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","The World Journal of Biological Psychiatry"],["dc.bibliographiccitation.lastpage","170"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Hasan, Alkomiet"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Wobrock, Thomas"],["dc.contributor.author","Lieberman, Jeffrey"],["dc.contributor.author","Glenthoj, Birte"],["dc.contributor.author","Gattaz, Wagner F."],["dc.contributor.author","Thibaut, Florence"],["dc.contributor.author","Moeller, Hans-Juergen"],["dc.date.accessioned","2018-11-07T09:59:10Z"],["dc.date.available","2018-11-07T09:59:10Z"],["dc.date.issued","2015"],["dc.description.abstract","These updated guidelines are based on the first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in the years 2005 and 2006. For this 2015 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations which are clinically and scientifically relevant. They are intended to be used by all physicians diagnosing and treating patients with schizophrenia. Based on the first version of these guidelines a systematic review, as well as a data extraction from national guidelines have been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and subsequently categorised into six levels of evidence (A-F) and five levels of recommendation (1-5). This third part of the updated guidelines covers the management of the following specific treatment circumstances: comorbid depression, suicidality, various comorbid substance use disorders (legal and illegal drugs), and pregnancy and lactation. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of patients with schizophrenia."],["dc.identifier.doi","10.3109/15622975.2015.1009163"],["dc.identifier.isi","352078300002"],["dc.identifier.pmid","25822804"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37530"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Informa Healthcare"],["dc.relation.issn","1814-1412"],["dc.relation.issn","1562-2975"],["dc.title","World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","17"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Der Nervenarzt"],["dc.bibliographiccitation.lastpage","+"],["dc.bibliographiccitation.volume","79"],["dc.contributor.author","Wobrock, Thomas"],["dc.contributor.author","D'Amelio, R."],["dc.contributor.author","Falkai, Peter Gaston"],["dc.date.accessioned","2018-11-07T11:20:28Z"],["dc.date.available","2018-11-07T11:20:28Z"],["dc.date.issued","2008"],["dc.description.abstract","Substance use disorder is the most common psychiatric comorbidity in patients with schizophrenia, revealing prevalence rates of up to 65%. Recommendations of antipsychotic pharmacotherapy in schizophrenia are based on studies excluding patients with this double diagnosis. In this systematic review the available pharmacological studies in this subgroup of patients are summarised and discussed with regard to evidence-based medicine. Most available studies concern small sample sizes, and the level of evidence in those studies was low. Data suggest efficacy for second-generation antipsychotics (SGAs) (aripiprazole, clozapine, olanzapine, quetiapine, and risperidone) superior to orally administered conventional antipsychotics. Treatment with SGAs revealed superior improvement of distinct psychopathological symptoms, similarly to those studies excluding patients with comorbid substance abuse. In some studies reduced craving and increased reduction of substance abuse could be demonstrated. Tricyclic antidepressants (TCAs) added to antipsychotic maintenance therapy showed efficacy in reducing substance abuse and craving, whereas studies with other antidepressive agents (e.g. selective serotonin reuptake inhibitors) are lacking. Administration of the anti-craving agents naltrexone and disulfiram led to a decrease of drug intake in a few studies. Unfortunately no studies are available using acamprosate in patients with schizophrenia and comorbid alcoholism. In conclusion the preferential use of SGAs in patients with schizophrenia and comorbid substance use disorder is suggested, and the early initiation of concomitant treatment with TCAs (depending on current psychopathological status) and anti-craving agents has to be considered."],["dc.identifier.doi","10.1007/s00115-007-2310-4"],["dc.identifier.isi","000252467600002"],["dc.identifier.pmid","17619840"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55540"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0028-2804"],["dc.title","Pharmacotherapy of schizophrenia and comorbid substance use disorder. A systematic review"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","719"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","The World Journal of Biological Psychiatry"],["dc.bibliographiccitation.lastpage","728"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Martins-De-Souza, Daniel"],["dc.contributor.author","Wobrock, Thomas"],["dc.contributor.author","Zerr, Inga"],["dc.contributor.author","Schmitt, Andrea"],["dc.contributor.author","Gawinecka, Joanna"],["dc.contributor.author","Schneider-Axmann, Thomas"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Turck, Christoph W."],["dc.date.accessioned","2018-11-07T08:41:14Z"],["dc.date.available","2018-11-07T08:41:14Z"],["dc.date.issued","2010"],["dc.description.abstract","Objectives. To identify proteins differentially expressed in schizophrenia patients, we collected 50 mu l cerebrospinal fluid from 17 first-episode schizophrenia patients and 10 healthy controls. Methods. Their proteins were separated by two-dimensional gel electrophoresis without using any depletion method and identified by mass spectrometry. Results. Approximately 550 spots were detected, six of which had significantly different intensities in schizophrenia compared to control specimens. We were able to validate in individual samples the upregulation of apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase by Western blot analyses and detect the downregulation of transthyretin, TGF-beta receptor type-1 and coiled-coil domain-containing protein 3 precursor. Conclusions. These findings may help to elucidate the disease mechanisms and confirm the hypothesis of disturbed cholesterol and phospholipid metabolism in schizophrenia, and thus reveal the final role players. Moreover, a grouped protein expression analysis of apolipoprotein E, apolipoprotein A-I, and prostaglandin-H2 D-isomerase in cerebrospinal fluid from patients might be a potential diagnostic tool for schizophrenia."],["dc.identifier.doi","10.3109/15622971003758748"],["dc.identifier.isi","000280009300005"],["dc.identifier.pmid","20446881"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19420"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Informa Healthcare"],["dc.relation.issn","1562-2975"],["dc.title","Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","397"],["dc.bibliographiccitation.journal","Schizophrenia Research"],["dc.bibliographiccitation.lastpage","407"],["dc.bibliographiccitation.volume","216"],["dc.contributor.author","Takahashi, Shun"],["dc.contributor.author","Keeser, Daniel"],["dc.contributor.author","Rauchmann, Boris-Stephan"],["dc.contributor.author","Schneider-Axmann, Thomas"],["dc.contributor.author","Keller-Varady, Katriona"],["dc.contributor.author","Maurus, Isabel"],["dc.contributor.author","Dechent, Peter"],["dc.contributor.author","Wobrock, Thomas"],["dc.contributor.author","Hasan, Alkomiet"],["dc.contributor.author","Schmitt, Andrea"],["dc.contributor.author","Ertl-Wagner, Birgit"],["dc.contributor.author","Malchow, Berend"],["dc.contributor.author","Falkai, Peter"],["dc.date.accessioned","2021-04-14T08:27:38Z"],["dc.date.available","2021-04-14T08:27:38Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1016/j.schres.2019.11.004"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82355"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.issn","0920-9964"],["dc.title","Effect of aerobic exercise combined with cognitive remediation on cortical thickness and prediction of social adaptation in patients with schizophrenia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1383"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Der Nervenarzt"],["dc.bibliographiccitation.lastpage","1384"],["dc.bibliographiccitation.volume","84"],["dc.contributor.author","Grossimlinghaus, I."],["dc.contributor.author","Falkai, Peter Gaston"],["dc.contributor.author","Gaebel, Wolfgang"],["dc.contributor.author","Janssen, Bert J. C."],["dc.contributor.author","Reich-Erkelenz, Daniela"],["dc.contributor.author","Wobrock, Thomas"],["dc.contributor.author","Zielasek, J."],["dc.date.accessioned","2018-11-07T09:18:01Z"],["dc.date.available","2018-11-07T09:18:01Z"],["dc.date.issued","2013"],["dc.identifier.isi","000327079400013"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28314"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1433-0407"],["dc.relation.issn","0028-2804"],["dc.title","On the Quality Indicators of the DGPPN Reply"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","26"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Der Nervenarzt"],["dc.bibliographiccitation.lastpage","33"],["dc.bibliographiccitation.volume","91"],["dc.contributor.author","Hasan, Alkomiet"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Lehmann, Isabel"],["dc.contributor.author","Janssen, Birgit"],["dc.contributor.author","Wobrock, Thomas"],["dc.contributor.author","Zielasek, Jürgen"],["dc.contributor.author","Gaebel, Wolfgang"],["dc.date.accessioned","2020-12-10T14:08:38Z"],["dc.date.available","2020-12-10T14:08:38Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1007/s00115-019-00813-y"],["dc.identifier.eissn","1433-0407"],["dc.identifier.issn","0028-2804"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70501"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Die aktualisierte S3-Leitlinie Schizophrenie"],["dc.title.alternative","Revised S3 guidelines on schizophrenia. Developmental process and selected recommendations"],["dc.title.subtitle","Entwicklungsprozess und ausgewählte Empfehlungen"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","350"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Der Nervenarzt"],["dc.bibliographiccitation.lastpage","+"],["dc.bibliographiccitation.volume","84"],["dc.contributor.author","Grossimlinghaus, I."],["dc.contributor.author","Falkai, Peter Gaston"],["dc.contributor.author","Gaebel, Wolfgang"],["dc.contributor.author","Janssen, Bert J. C."],["dc.contributor.author","Reich-Erkelenz, Daniela"],["dc.contributor.author","Wobrock, Thomas"],["dc.contributor.author","Zielasek, J."],["dc.date.accessioned","2018-11-07T09:27:32Z"],["dc.date.available","2018-11-07T09:27:32Z"],["dc.date.issued","2013"],["dc.description.abstract","Valid and feasible quality indicators can measure healthcare quality and show potential for improvement in care. The German Association for Psychiatry and Psychotherapy (DGPPN) has developed trans-sectoral quality indicator sets for four mental disorders with high prevalence (alcohol dependence, dementia, depression and schizophrenia). The DGPPN followed a structured multistage process and used guideline recommendations and the results of systematic evidence searches as the basis for the development of these quality indicators. This was followed by a structured consensus process for all quality indicators. Four evidence and consensus-based, diagnosis-specific and trans-sectoral quality indicator sets have been developed. It is possible to develop quality indicators on the basis of guideline recommendations. The implementation of the DGPPN quality indicators will play a crucial role in order to evaluate their utility and feasibility as quality measures for German mental healthcare."],["dc.identifier.doi","10.1007/s00115-012-3705-4"],["dc.identifier.isi","000316223200008"],["dc.identifier.pmid","23494246"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30560"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1433-0407"],["dc.relation.issn","0028-2804"],["dc.title","Developmental process of DGPPN quality indicators"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","127"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neuroscience"],["dc.bibliographiccitation.lastpage","136"],["dc.bibliographiccitation.volume","265"],["dc.contributor.author","Kittel-Schneider, Sarah"],["dc.contributor.author","Wobrock, Thomas"],["dc.contributor.author","Scherk, Harald"],["dc.contributor.author","Schneider-Axmann, Thomas"],["dc.contributor.author","Trost, Sarah"],["dc.contributor.author","Zilles, David"],["dc.contributor.author","Wolf, C."],["dc.contributor.author","Schmitt, A."],["dc.contributor.author","Malchow, Berend"],["dc.contributor.author","Hasan, Alkomiet"],["dc.contributor.author","Backens, Martin"],["dc.contributor.author","Reith, W."],["dc.contributor.author","Falkai, Peter Gaston"],["dc.contributor.author","Gruber, Oliver"],["dc.contributor.author","Reif, A."],["dc.date.accessioned","2018-11-07T10:00:31Z"],["dc.date.available","2018-11-07T10:00:31Z"],["dc.date.issued","2015"],["dc.description.abstract","The diacylglycerol kinase eta (DGKH) gene, first identified in a genome-wide association study, is one of the few replicated risk genes of bipolar affective disorder (BD). Following initial positive studies, it not only was found to be associated with BD but also implicated in the etiology of other psychiatric disorders featuring affective symptoms, rendering DGKH a cross-disorder risk gene. However, the (patho-)physiological role of the encoded enzyme is still elusive. In the present study, we investigated primarily the influence of a risk haplotype on amygdala volume in patients suffering from schizophrenia or BD as well as healthy controls and four single nucleotide polymorphisms conveying risk. There was a significant association of the DGKH risk haplotype with increased amygdala volume in BD, but not in schizophrenia or healthy controls. These findings add to the notion of a role of DGKH in the pathogenesis of BD."],["dc.description.sponsorship","DFG [RTG 1253/1, RE1632/5-1]; BMBF (DZHI) [01EO1004]; IZKF [Z3-24]"],["dc.identifier.doi","10.1007/s00406-014-0513-9"],["dc.identifier.isi","000350305500005"],["dc.identifier.pmid","24958494"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37825"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","1433-8491"],["dc.relation.issn","0940-1334"],["dc.title","Influence of DGKH variants on amygdala volume in patients with bipolar affective disorder and schizophrenia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","379"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","International Review of Psychiatry"],["dc.bibliographiccitation.lastpage","387"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Gaebel, Wolfgang"],["dc.contributor.author","Riesbeck, Mathias"],["dc.contributor.author","Wobrock, Thomas"],["dc.date.accessioned","2018-11-07T09:01:29Z"],["dc.date.available","2018-11-07T09:01:29Z"],["dc.date.issued","2011"],["dc.description.abstract","Treatment guidelines provide evidence-based recommendations to assist practitioners in specific clinical situations. They are a major tool to assure and enhance treatment quality and to overcome existing disparities. However, guideline quality itself varies and needs to be considered. Based on a former review, schizophrenia guidelines with high methodological quality were identified and examined regarding updated versions. Five guidelines were selected, of which three updates have been newly evaluated with the AGREE instrument. In addition, clinical content regarding seven core topics in schizophrenia treatment decisions was compared. Guideline quality on average is good, with highest AGREE scores for the NICE guideline. Updating of the German guideline resulted in noticeable quality improvements. Regarding content, recommendations largely correspond in five areas across guidelines, whereas discrepancies or vagueness exist in two areas due to newly emerging (drug choice) or still restricted evidence (duration of antipsychotic treatment). There are increasing efforts to develop guidelines with improved quality. Also, there is a need to equalize and improve healthcare quality across countries. Since many formal and content-related issues are 'universal', development of trans-national guidelines seems indicated. Nevertheless, core guideline recommendations should be adapted to regional conditions using available tools for adaptation."],["dc.identifier.doi","10.3109/09540261.2011.606801"],["dc.identifier.isi","000296233100011"],["dc.identifier.pmid","22026495"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24438"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Informa Healthcare"],["dc.relation.issn","0954-0261"],["dc.title","Schizophrenia guidelines across the world: A selective review and comparison"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","589"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neuroscience"],["dc.bibliographiccitation.lastpage","600"],["dc.bibliographiccitation.volume","265"],["dc.contributor.author","Hasan, Alkomiet"],["dc.contributor.author","Wolff-Menzler, Claus"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Weidinger, Elif"],["dc.contributor.author","Jobst, Andrea"],["dc.contributor.author","Hoell, Imke"],["dc.contributor.author","Malchow, Berend"],["dc.contributor.author","Yeganeh-Doost, Peyman"],["dc.contributor.author","Strube, Wolfgang"],["dc.contributor.author","Quast, Silke"],["dc.contributor.author","Mueller, Norbert"],["dc.contributor.author","Wobrock, Thomas"],["dc.date.accessioned","2018-11-07T09:51:15Z"],["dc.date.available","2018-11-07T09:51:15Z"],["dc.date.issued","2015"],["dc.description.abstract","Despite many pharmacological and psychosocial treatment options, schizophrenia remains a debilitating disorder. Thus, new treatment strategies rooted in the pathophysiology of the disorder are needed. Recently, vagus nerve stimulation (VNS) has been proposed as a potential treatment option for various neuropsychiatric disorders including schizophrenia. The objective of this study was to investigate for the first time the feasibility, safety and efficacy of transcutaneous VNS in stable schizophrenia. A bicentric randomized, sham-controlled, double-blind trial was conducted from 2010 to 2012. Twenty schizophrenia patients were randomly assigned to one of two treatment groups. The first group (active tVNS) received daily active stimulation of the left auricle for 26 weeks. The second group (sham tVNS) received daily sham stimulation for 12 weeks followed by 14 weeks of active stimulation. Primary outcome was defined as change in the Positive and Negative Symptom Scale total score between baseline and week 12. Various other secondary measures were assessed to investigate safety and efficacy. The intervention was well tolerated with no relevant adverse effects. We could not observe a statistically significant difference in the improvement of schizophrenia psychopathology during the observation period. Neither psychopathological and neurocognitive measures nor safety measures showed significant differences between study groups. Application of tVNS was well tolerated, but did not improve schizophrenia symptoms in our 26-week trial. While unsatisfactory compliance questions the feasibility of patient-controlled neurostimulation in schizophrenia, the overall pattern of symptom change might warrant further investigations in this population."],["dc.description.sponsorship","CerboMed GmbH, Erlangen, Germany"],["dc.identifier.doi","10.1007/s00406-015-0618-9"],["dc.identifier.isi","000361397100006"],["dc.identifier.pmid","26210303"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35876"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","1433-8491"],["dc.relation.issn","0940-1334"],["dc.title","Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]